3-(6-Chloro-1-methyl-1H-indol-3-yl)-4-(5-methoxy-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione | 202807-20-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(6-Chloro-1-methyl-1H-indol-3-yl)-4-(5-methoxy-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione
• 英文别名: 3-(6-Chloro-1-methylindol-3-yl)-4-(5-methoxy-1-methylindol-3-yl)pyrrole-2,5-dione
• CAS: 202807-20-3
• 化学式: C₂₃H₁₈ClN₃O₃
• 分子量: 419.867
• InChiKey: ZKSVMVQOZGPIAY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  65.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-(5-methoxy-1-methyl-1H-indol-3-yl)-acetimidic acid isopropyl ester hydrochloride 、 (6-chloro-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride 生成 3-(6-Chloro-1-methyl-1H-indol-3-yl)-4-(5-methoxy-1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione
  参考文献：
  名称：

  Substituted pyrroles

  摘要：

  化合物的公式为其中R1和R1'分别独立地为烷基、芳基、烯基或炔基；R2和R2'分别独立地为氢、烷基、芳基烷基、烷氧基烷基、羟基烷基、卤代烷基、氨基烷基、单烷基氨基烷基、双烷基氨基烷基、酰胺基烷基、烷基磺酰胺基烷基、芳基磺酰胺基烷基、巯基烷基、烷硫基烷基、羧基烷基、烷氧羰基烷基、氨基羰基烷基、烷硫基或烷基亚磺酰基；R4、R5、R6、R7、R4'、R5'、R6'和R7'各自独立地为氢、CO2R9、CH2OR10、CHO、CH2NR11R12、CON(R13)2、卤素、氰基、芳基、烷基、羟基、烷氧基、芳氧基、卤代烷基、硝基、氨基、芳基氧基、酰胺基、单烷基氨基、双烷基氨基、硫基、烷基、烷基亚磺酰基、烷基磺酰基、芳基亚磺酰基、偶氮基、磷酸酯或膦酸酯，但至少有R4、R5、R6和R7中的一个和R4'、R5'、R6'和R7'中的一个不是氢，如果R6是甲氧基，则R5或R5'不是甲氧基；R8为烷基或芳基；R9为烷基或芳基；R10为氢、烷基或芳基；R11和R12独立地为氢、烷基、芳基、芳基烷基或酰基；R13为氢、烷基、芳基或芳基烷基；X和Y中的一个表示O，另一个表示O、S、(H,OH)或(H,H)；以及公式I的酸性化合物的药学上可接受的前药或与酸的公式I的碱性化合物的药学上可接受的盐是抗增殖剂，可用于癌症的治疗。

  公开号：

  US06228877B1

文献信息

• SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0915870A1

  公开（公告）日：1999-05-19
• US6228877B1
  申请人：——

  公开号：US6228877B1

  公开（公告）日：2001-05-08
• [EN] SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION<br/>[FR] BIS-INDOLYLMALEIMIDES SUBSTITUES DESTINES A INHIBER LA PROLIFERATION CELLULAIRE
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：WO1998004551A1

  公开（公告）日：1998-02-05

  (EN) Compounds of formula (I) wherein: R1 and R1' are independently alkyl, aryl, alkenyl or alkynyl; R2 and R2' are independently hydrogen, alkyl, aralkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, acylaminoalkyl, alkylsulphonylaminoalkyl, arylsulphonyl-aminoalkyl, mercaptoalkyl, alkylthioalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkylthio or alkylsulphinyl; R4, R5, R6, R7, R4', R5', R6' and R7' each independently are hydrogen, formula (II), CO2R9, CH2OR10, CHO, CH2NR11R12, CON(R13)2, halogen, cyano, aryl, alkyl, hydroxy, alkoxy, aryloxy, haloalkyl, nitro, amino, aralkyloxy, acylamino, monoalkylamino, dialkylamino, thio, alkylthio, alkylsulphinyl, alkylsulphonyl, arylsulphinyl, azide, phosphate or phosphonate provided that at least one of R4, R5, R6 and R7 and at least one of R4', R5', R6' and R7' are other than hydrogen, with the proviso that when R6 is methoxy, R5 or R5' are not methoxy; R8 is alkyl or aryl; R9 is alkyl or aryl; R10 is hydrogen, alkyl or aryl; R11 and R12 are independently hydrogen, alkyl, aryl, aralkyl or acyl; R13 is hydrogen, alkyl, aryl or aralkyl; and one of X and Y signifies O and the other signifies O, S, (H,OH) or (H,H); as well as pharmaceutically acceptable prodrugs therefor or pharmaceutically acceptable salts of acidic compounds of formula (I) with basis or basic compounds of formula (I) with acids are antiproliferative agents useful in the treatment of cancer.(FR) L'invention concerne des composés de formule (I), dans laquelle R1 et R1' sont indépendamment alkyle, aryle, alcényle ou alkynyle; R2 et R2' sont indépendamment hydrogène, alkyle, aralkyle, alcoxyalkyle, hydroxyalkyle, haloalkyle, aminoalkyle, monoalkylaminoalkyle, dialkylaminoalkyle, acylaminoalkyle, alkylsulfonylaminoalkyle, arylsulfonylaminoalkyle, mercaptoalkyle, alkylthioalkyle, carboxyalkyle, alcoxycarbonylalkyle, aminocarbonylalkyle, alkylthio ou alkylsulfinyle; R4, R5, R6, R7, R4', R5', R6' et R7' sont indépendamment hydrogène, (II), CO2R9, CH2OR10, CHO, CH2NR11R12, CON(R13)2, halogène, cyano, aryle, alkyle, hydroxy, alcoxy, aryloxy, haloalkyle, nitro, amino, aralkyloxy, acylamino, monoalkylamino, dialkylamino, thio, alkylthio, alkylsulfinyle, alkylsulfonyle, arylsulfinyle, azide, phosphate ou phosphonate, à condition qu'au moins R4, R5, R6 et/ou R7 et au moins R4', R5', R6' et/ou R7' soient autres qu'hydrogène, à condition que quand R6 est méthoxy, R5 ou R5' ne soit pas méthoxy; R8 est alkyle ou aryle; R9 est alkyle ou aryle; R10 est hydrogène, alkyle ou aryle; R11 et R12 sont indépendamment hydrogène, alkyle, aryle, aralkyle ou acyle; R13 est hydrogène, alkyle, aryle ou aralkyle; et X ou Y signifie O et l'autre signifie O, S, (H,OH) ou (H,H). L'invention concerne également des promédicaments pharmaceutiquement acceptables pour ces composés, ou des sels pharmaceutiquement acceptables de composés acides de formule (I) avec des bases ou de composés basiques de formule (I) avec des acides. Ces composés sont des agents antiprolifératifs utiles dans le traitement du cancer.
• Substituted pyrroles
  申请人：Hoffmann-La Roche Inc.

  公开号：US06228877B1

  公开（公告）日：2001-05-08

  Compounds of the formula wherein R1 and R1′ are independently alkyl, aryl, alkenyl or alkynyl; R2 and R2′ are independently hydrogen, alkyl, aralkyl, alkoxyalkyl, hydroxyalkyl, haloalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, acylaminoalkyl, alkylsulphonylaminoalkyl, arylsulphonyl-aminoalkyl, mercaptoalkyl, alkylthioalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkylthio or alkylsulphinyl; R4, R5, R6, R7, R4′, R5′, R6′, and R7′ each independently are hydrogen, CO2R9, CH2OR10, CHO, CH2NR11R12, CON(R13)2, halogen, cyano, aryl, alkyl, hydroxy, alkoxy, aryloxy, haloalkyl, nitro, amino, aralkyloxy, acylamino, monoalkylamino, dialkylamino, thio, alkyl, alkylsulphinyl, alkylsulphonyl, arylsulphinyl, azide, phosphate or phosphonate provided that at least one of R4, R5, R6 and R7 and at least one of R4′, R5′, R6′, and R7′ are other than hydrogen, with the proviso that when R6 is methoxy, R5 or R5′ are not methoxy; R8 is alkyl or aryl; R9 is alkyl or aryl; R10 is hydrogen, alkyl or aryl; R11 and R12 are independently hydrogen, alkyl, aryl, aralkyl or acyl; R13 is hydrogen, alkyl, aryl or aralkyl; and one of X and Y signifies O and the other signifies O, S, (H,OH) or (H,H); as well as pharmaceutically acceptable prodrugs or pharmaceutically acceptable salts of acidic compounds of formula I with bases and or basic compounds of formula I with acids are antiproliferative agents useful in the treatment of cancer.

  化合物的公式为其中R1和R1'分别独立地为烷基、芳基、烯基或炔基；R2和R2'分别独立地为氢、烷基、芳基烷基、烷氧基烷基、羟基烷基、卤代烷基、氨基烷基、单烷基氨基烷基、双烷基氨基烷基、酰胺基烷基、烷基磺酰胺基烷基、芳基磺酰胺基烷基、巯基烷基、烷硫基烷基、羧基烷基、烷氧羰基烷基、氨基羰基烷基、烷硫基或烷基亚磺酰基；R4、R5、R6、R7、R4'、R5'、R6'和R7'各自独立地为氢、CO2R9、CH2OR10、CHO、CH2NR11R12、CON(R13)2、卤素、氰基、芳基、烷基、羟基、烷氧基、芳氧基、卤代烷基、硝基、氨基、芳基氧基、酰胺基、单烷基氨基、双烷基氨基、硫基、烷基、烷基亚磺酰基、烷基磺酰基、芳基亚磺酰基、偶氮基、磷酸酯或膦酸酯，但至少有R4、R5、R6和R7中的一个和R4'、R5'、R6'和R7'中的一个不是氢，如果R6是甲氧基，则R5或R5'不是甲氧基；R8为烷基或芳基；R9为烷基或芳基；R10为氢、烷基或芳基；R11和R12独立地为氢、烷基、芳基、芳基烷基或酰基；R13为氢、烷基、芳基或芳基烷基；X和Y中的一个表示O，另一个表示O、S、(H,OH)或(H,H)；以及公式I的酸性化合物的药学上可接受的前药或与酸的公式I的碱性化合物的药学上可接受的盐是抗增殖剂，可用于癌症的治疗。